{"nctId":"NCT00130832","briefTitle":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","startDateStruct":{"date":"2005-10"},"conditions":["Rotavirus Infections","Gastroenteritis"],"count":735,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent","Biological: Comparator: Oral Poliovirus Vaccine (OPV)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent","Biological: Comparator: Oral Poliovirus Vaccine (OPV) (staggered)"]}],"interventions":[{"name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":[]},{"name":"Comparator: Oral Poliovirus Vaccine (OPV)","otherNames":[]},{"name":"Comparator: Oral Poliovirus Vaccine (OPV) (staggered)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infants in good health\n\nExclusion Criteria:\n\n* Previous administration of any oral poliovirus vaccine (OPV) and rotavirus vaccine\n* Receipt of inactivated poliovirus vaccine (IPV) prior to the first dose of either study vaccine, or at any time during the course of the study\n* Any condition resulting in depressed immunity\n* Any allergy to any vaccine component as stated in the package circulars\n* Allergies to polymyxin B, neomycin or any other antibiotics\n* Receipt of intramuscular, oral, or intravenous corticosteroid treatment\n* History of congenital abdominal disorders, intussusception, or abdominal surgery; clinical evidence of active gastrointestinal illness\n* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive\n* Prior receipt of a blood transfusion or blood products, including immunoglobulin\n* Fever, with a rectal temperature of ≥38.1°C (≥ 100.5°F) at the time of immunization\n* Infants residing in a household with an immunocompromised person","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3","description":"GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"888.0","spread":null},{"groupId":"OG001","value":"1139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"814.9","spread":null},{"groupId":"OG001","value":"814.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.6","spread":null},{"groupId":"OG001","value":"269.2","spread":null}]}]}]},{"type":"PRIMARY","title":"GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)","description":"GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154.9","spread":null},{"groupId":"OG001","value":"292.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered","description":"Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.8","spread":null},{"groupId":"OG001","value":"182.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null},{"groupId":"OG001","value":"74.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"131.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":366},"commonTop":["Pyrexia","Diarrhoea","Vomiting","Nasopharyngitis","Cough"]}}}